Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells.
Zhou L, Huntington K, Zhang S, Carlsen L, So EY, Parker C, Sahin I, Safran H, Kamle S, Lee CM, Lee CG, Elias JA, Campbell KS, Naik MT, Atwood WJ, Youssef E, Pachter JA, Navaraj A, Seyhan AA, Liang O, El-Deiry WS. Zhou L, et al. Among authors: safran h. bioRxiv [Preprint]. 2020 Sep 2:2020.08.02.230839. doi: 10.1101/2020.08.02.230839. bioRxiv. 2020. PMID: 32793908 Free PMC article. Preprint.
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, Carneiro B, Raufi A, Huntington K, Carlsen L, Louie A, Safran H, Seyhan AA, Tarapore RS, Schalop L, Stogniew M, Allen JE, Oster W, El-Deiry WS. Prabhu VV, et al. Among authors: safran h. Neoplasia. 2020 Dec;22(12):725-744. doi: 10.1016/j.neo.2020.09.005. Epub 2020 Oct 23. Neoplasia. 2020. PMID: 33142238 Free PMC article. Review.
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection.
Zhou L, Huntington K, Zhang S, Carlsen L, So EY, Parker C, Sahin I, Safran H, Kamle S, Lee CM, Geun Lee C, A Elias J, S Campbell K, T Naik M, J Atwood W, Youssef E, A Pachter J, Navaraj A, A Seyhan A, Liang O, El-Deiry WS. Zhou L, et al. Among authors: safran h. Oncotarget. 2020 Nov 17;11(46):4201-4223. doi: 10.18632/oncotarget.27799. eCollection 2020 Nov 17. Oncotarget. 2020. PMID: 33245731 Free PMC article.
Strategies to sensitize cancer cells to immunotherapy.
George A, Sahin I, Carneiro BA, Dizon DS, Safran HP, El-Deiry WS. George A, et al. Hum Vaccin Immunother. 2021 Aug 3;17(8):2595-2601. doi: 10.1080/21645515.2021.1891817. Epub 2021 May 21. Hum Vaccin Immunother. 2021. PMID: 34019474 Free PMC article.
EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y, Zhou L, Safran H, Borsuk R, Lulla R, Tapinos N, Seyhan AA, El-Deiry WS. Zhang Y, et al. Among authors: safran h. Neoplasia. 2021 Aug;23(8):792-810. doi: 10.1016/j.neo.2021.06.007. Epub 2021 Jul 8. Neoplasia. 2021. PMID: 34246076 Free PMC article.
Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma.
Hsu A, Huntington KE, De Souza A, Zhou L, Olszewski AJ, Makwana NP, Treaba DO, Cavalcante L, Giles FJ, Safran H, El-Deiry WS, Carneiro BA. Hsu A, et al. Among authors: safran h. Cancer Biol Ther. 2022 Dec 31;23(1):417-423. doi: 10.1080/15384047.2022.2088984. Cancer Biol Ther. 2022. PMID: 35815408 Free PMC article.
Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379).
Almhanna K, Breakstone R, Raufi A, Wood R, Webber A, Dionson S, Cavanagh L, Seyhan AA, Safran H, El-Deiry W. Almhanna K, et al. Among authors: safran h. Transl Gastroenterol Hepatol. 2024 Mar 15;9:15. doi: 10.21037/tgh-23-69. eCollection 2024. Transl Gastroenterol Hepatol. 2024. PMID: 38716219 Free PMC article.
166 results